ARTICLE | Company News
BTG, Onyx deal
November 10, 2008 8:00 AM UTC
BTG granted Onyx exclusive, worldwide rights to develop and commercialize BGC 945 to treat cancer. The thymidylate synthase inhibitor, now called ONX 0801, is in preclinical testing. BTG will recei...